← Syros Pharmaceuticals, Inc. (SYRS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Syros Pharmaceuticals, Inc. (SYRS)
Pharmaceutical Preparations · market cap $59M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Syros Pharmaceuticals (SYRS) is a small-cap pharmaceutical company with 68 employees and a market cap of approximately $59M, currently trading near $0 per share. Its sole disclosed pipeline asset is tamibarotene, a Phase 2 candidate being evaluated in Acute Myeloid Leukemia. The dossier is severely data-limited: financials, cash runway, dilution history, institutional ownership, and short interest are all undisclosed in the provided facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tamibarotene | Phase 2 | Acute Myeloid Leukemia |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SYRS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.